Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) Sees Large Decline in Short Interest

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) was the recipient of a significant decrease in short interest in June. As of June 30th, there was short interest totaling 6,372 shares, a decrease of 35.7% from the June 15th total of 9,904 shares. Currently, 0.1% of the shares of the company are short sold. Based on an average daily volume of 8,436 shares, the days-to-cover ratio is currently 0.8 days.

Institutional Investors Weigh In On Cryo-Cell International

A hedge fund recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP bought a new position in Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) in the third quarter, according to the company in its most recent disclosure with the SEC. The fund bought 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned 0.14% of Cryo-Cell International at the end of the most recent quarter. Institutional investors and hedge funds own 10.44% of the company’s stock.

Cryo-Cell International Price Performance

NYSEAMERICAN CCEL traded up $0.13 during trading hours on Friday, hitting $3.61. The company’s stock had a trading volume of 13,284 shares, compared to its average volume of 12,321. Cryo-Cell International has a 12 month low of $2.72 and a 12 month high of $5.43. The company’s 50 day simple moving average is $3.52 and its two-hundred day simple moving average is $3.45. The company has a market cap of $29.10 million, a P/E ratio of -12.03 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last announced its quarterly earnings results on Wednesday, July 15th. The company reported $0.07 earnings per share (EPS) for the quarter. The company had revenue of $7.78 million for the quarter.

About Cryo-Cell International

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.